Free Trial
NASDAQ:HRMY

Harmony Biosciences (HRMY) Stock Price, News & Analysis

Harmony Biosciences logo
$34.92 +0.03 (+0.07%)
As of 01:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Harmony Biosciences Stock (NASDAQ:HRMY)

Key Stats

Today's Range
$33.97
$35.30
50-Day Range
$32.39
$40.46
52-Week Range
$28.14
$41.61
Volume
214,934 shs
Average Volume
566,345 shs
Market Capitalization
$1.99 billion
P/E Ratio
16.52
Dividend Yield
N/A
Price Target
$53.67
Consensus Rating
Buy

Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

HRMY MarketRank™: 

Harmony Biosciences scored higher than 95% of companies evaluated by MarketBeat, and ranked 68th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Harmony Biosciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Harmony Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Harmony Biosciences are expected to grow by 30.04% in the coming year, from $2.43 to $3.16 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harmony Biosciences is 16.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harmony Biosciences is 16.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.16.

  • Price to Earnings Growth Ratio

    Harmony Biosciences has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Harmony Biosciences has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Harmony Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    9.32% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently decreased by 31.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Harmony Biosciences does not currently pay a dividend.

  • Dividend Growth

    Harmony Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.32% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently decreased by 31.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Harmony Biosciences has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Harmony Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    8 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,831,679.00 in company stock.

  • Percentage Held by Insiders

    30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harmony Biosciences' insider trading history.
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Stock News Headlines

Do this Before Elon’s Reveal on March 17th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Harmony Biosciences price target lowered to $42 from $52 at Mizuho
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down on Analyst Downgrade
See More Headlines

HRMY Stock Analysis - Frequently Asked Questions

Harmony Biosciences' stock was trading at $34.41 at the beginning of the year. Since then, HRMY stock has increased by 1.2% and is now trading at $34.8150.
View the best growth stocks for 2025 here
.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, October, 29th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences's revenue was up 16.0% compared to the same quarter last year.

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Top institutional shareholders of Harmony Biosciences include Valor Management LLC (11.60%), FMR LLC (9.35%), Vanguard Group Inc. (8.30%) and Pacer Advisors Inc. (4.00%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks.
View institutional ownership trends
.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
10/29/2024
Today
2/21/2025
Next Earnings (Estimated)
4/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRMY
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.67
High Stock Price Target
$75.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+53.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$128.85 million
Pretax Margin
25.71%

Debt

Sales & Book Value

Annual Sales
$681.88 million
Cash Flow
$2.58 per share
Book Value
$7.97 per share

Miscellaneous

Free Float
39,465,000
Market Cap
$1.99 billion
Optionable
Optionable
Beta
0.80
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:HRMY) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners